O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Data from the first in human study on O3R-5671’s potent TNFα inhibition Studies in ulcerative colitis and psoriasis to initiate in H2 2026 Leuven, Belgium. February 20, 2025. Onco3R Therapeutics,